Table 3

Survival and progression-free survival (PFS) in 77 patients with medulloblastoma

Variable5-year PFS5-year survival
%95% CIa%95% CI
All patients6756–777160–81
Sex
 Female (n = 25)7254–897254–90
 Male (n = 52)6451–787058–83
Age at diagnosis
 <3 yr (n = 22)5231–745837–79
 ≥3 yr (n = 55)7260–847665–87
Metastatic stage
 M0 (n = 59)7159–837969–90
 M1–3 (n = 15)4421–675329–77
Surgery
 ≥90% resection (n = 58)7261–847462–85
 ≥50% but <90% resection (n = 19)5027–736240–84
Therapy
 XRT ≥50 Gy + chemotherapy (n = 55)6857–807361–84
 XRT ≥50 Gy or chemotherapy alone (n = 21)5830–866235–88
Caspase-8 expression
 Weak (n = 13)314–594718–77
 Moderate/strong (n = 64)7362–847564–86
Caspase-9 expression
 Weak (n = 18)5633–796139–84
 Moderate/strong (n = 59)7058–827462–85
  • a CI, confidence interval; XRT, local radiation therapy.